Graybug Vision to Participate in Upcoming Industry Conferences

Redwood City, CA – November 6, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced that Jeffrey L. Cleland, Ph.D., President and CEO, will present at the following upcoming investor and industry conferences:

  • Stifel 2017 Healthcare Conference
    Lotte New York Palace Hotel, New York City
    Wednesday, November 15 at 2:00 pm – 2:40 pm
  • 29th Annual Piper Jaffray Healthcare Conference
    Lotte New York Palace Hotel, New York City
    Tuesday, November 28 at 3:50 pm – 4:10 pm

Graybug Vision’s lead product, GB-102, is a novel injectable depot formulation containing a compound that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR) with the potential to reduce the treatment of wet AMD to two intravitreal injections per year.  A Phase 1/2 study of GB-102 in wet AMD patients was recently initiated.  The first part of this study consists of an open label single ascending dose of GB-102 in wet AMD patients that have previously received anti-VEGF therapy.  Monthly assessments for safety, pharmacology (retinal fluid) and efficacy (visual acuity) are being conducted after the GB-102 injection. A second-generation GB-102 product, GB-103, for potential once per year treatment of wet AMD is also in preclinical development.  In addition, preclinical studies are ongoing to select one or more novel compounds for the twice per year treatment of glaucoma.

About Wet AMD
Wet (neovascular) age-related macular degeneration (wet AMD), is the leading cause of blindness in the developed world in individuals aged 50 years or older. It is caused by the formation of abnormal and leaky new blood vessels behind the retina, termed choroidal neovascularization. The leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. According to the National Eye Institute, the prevalence of wet AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in the U.S.

About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases.  The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD.  Graybug Vision has developed a library of compounds to treat glaucoma, a leading cause of progressive, irreversible vision loss worldwide, by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year.
For more information, please visit

Jeff Cleland



Related News

Press release

Joint Statement on Retina Clinical Trials and COVID-19

To our Colleagues in the Retina Clinical Trials Community: We all take the health and safety of patients, healthcare providers, and our local communities very seriously, and the ongoing pandemic is challenging healthcare delivery and Read more…

Press release

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months

REDWOOD CITY, Calif., March 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today announced the early closing of Read more…

Press release

Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual Meeting

REDWOOD CITY, Calif., February 28, 2020 – Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today presented pre-clinical study results for GB-401, a novel injectable Read more…